# CS Capital

> CS Capital is a VC fund in Shanghai backing Biotechnology and Medical. See 21 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 21
- Last investment: Jun 2026
- Lead investor: 38%
- Last updated: Aug 2026
- Website: http://www.cscapital.cn/

CS Capital is an investment firm that offers investment management service.

## Contacts

5 contacts available for CS Capital. Shizune tracks 2 team members at CS Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cs-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 52% |
| Medical | 8 | 38% |
| Health Care | 8 | 38% |
| Biopharma | 3 | 14% |
| Pharmaceutical | 3 | 14% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 43% |
| Series A | 5 | 24% |
| Seed | 3 | 14% |
| Series C | 2 | 10% |
| Series D | 1 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 18 | 86% |
| United States | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Min Lou | CEO & Co-founder | 0 | https://shizune.co/investors/profile/min-lou-a1e0 |
| Yinghui Wu | Partner | 1 | https://shizune.co/investors/profile/yinghui-wu-0804 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Junhemeng Biopharmaceutical | Junhemeng is a research and development company of recombinant protein drugs. | $29.5M | Series C | Jun 08, 2026 |  |
| Tianyikang Biotechnology | Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products. |  | Seed | Feb 09, 2026 |  |
| Changfeng Bio | Changfeng Bio is the developer of biomedical material technologies, focused on addressing clinical challenges across medical disciplines. |  | Seed | Sep 12, 2025 |  |
| Lingmo Medical | Lingmo Medical is a company that provides department-level flexible endoscopic solutions.It is advancing the development of flexible endoscopy and providing higher-quality endoscopic solutions for clinicians and patients, allowing more risk categories to benefit from it. Benefit from endoscopic diagnosis and treatment. |  | Series A | Apr 07, 2025 |  |
| Hengyu Biotechnology | Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. | $27.8M | Series B | Mar 11, 2024 |  |
| Weimu Medical | Weimu Medical is a high-end interventional medical device developer. | $14M | Series A | Dec 06, 2023 |  |
| Baiying Bio | Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression inmammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers. | $72.6M | Series B | Aug 31, 2022 |  |
| Biointron | Biointron is committed to providing high-quality and economic recombinant protein/antibody reagents. The company was founded in 2012 and is headquartered in Shanghai, China. | $72.6M | Series B | Aug 31, 2022 |  |
| Porton Advanced Solutions | Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To meet the therapeutic product needs of our clients at the pre-clinical, clinical, and commercial stages, we offer end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services. | $80M | Series B | Aug 21, 2022 |  |
| Hengyu Biotechnology | Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. |  | Series A | Jul 25, 2022 |  |

10 of 21 investments shown.

## Co-investors
- [Chengshu Investment](https://shizune.co/investors/profile/chengshu-investment) — VC Fund, 3 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 2 deals together
- [ALAN AMC](https://shizune.co/investors/profile/alan-amc) — VC Fund, 2 deals together
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 2 deals together
- [Binfu Capital](https://shizune.co/investors/profile/binfu-capital) — VC Fund, 2 deals together
- [CMG-SDIC Capital Management](https://shizune.co/investors/profile/cmg-sdic-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Wellness Investors in China](https://shizune.co/investors/wellness-investors-china)
- [Wellness VC Funds in China](https://shizune.co/investors/wellness-vc-funds-china)

## FAQ

### What does CS Capital invest in?

CS Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CS Capital?

Public channels for CS Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CS Capital?

The team at CS Capital includes Min Lou (CEO & Co-founder) and Yinghui Wu (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co